Cargando…

HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors

BACKGROUND: Hairy and enhancer of split 1 (HES1), a basic helix-loop-helix transcriptional repressor, is a downstream target of Notch signaling. Notch signaling and HES1 expression have been linked to growth and survival in a variety of human cancer types and have been associated with increased meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Dailey, Deanna D, Anfinsen, Kristin P, Pfaff, Liza E, Ehrhart, EJ, Charles, J Brad, Bønsdorff, Tina B, Thamm, Douglas H, Powers, Barbara E, Jonasdottir, Thora J, Duval, Dawn L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701487/
https://www.ncbi.nlm.nih.gov/pubmed/23816051
http://dx.doi.org/10.1186/1746-6148-9-130
_version_ 1782275648669089792
author Dailey, Deanna D
Anfinsen, Kristin P
Pfaff, Liza E
Ehrhart, EJ
Charles, J Brad
Bønsdorff, Tina B
Thamm, Douglas H
Powers, Barbara E
Jonasdottir, Thora J
Duval, Dawn L
author_facet Dailey, Deanna D
Anfinsen, Kristin P
Pfaff, Liza E
Ehrhart, EJ
Charles, J Brad
Bønsdorff, Tina B
Thamm, Douglas H
Powers, Barbara E
Jonasdottir, Thora J
Duval, Dawn L
author_sort Dailey, Deanna D
collection PubMed
description BACKGROUND: Hairy and enhancer of split 1 (HES1), a basic helix-loop-helix transcriptional repressor, is a downstream target of Notch signaling. Notch signaling and HES1 expression have been linked to growth and survival in a variety of human cancer types and have been associated with increased metastasis and invasiveness in human osteosarcoma cell lines. Osteosarcoma (OSA) is an aggressive cancer demonstrating both high metastatic rate and chemotherapeutic resistance. The current study examined expression of Notch signaling mediators in primary canine OSA tumors and canine and human osteosarcoma cell lines to assess their role in OSA development and progression. RESULTS: Reverse transcriptase - quantitative PCR (RT-qPCR) was utilized to quantify HES1, HEY1, NOTCH1 and NOTCH2 gene expression in matched tumor and normal metaphyseal bone samples taken from dogs treated for appendicular OSA at the Colorado State University Veterinary Teaching Hospital. Gene expression was also assessed in tumors from dogs with a disease free interval (DFI) of <100 days compared to those with a DFI > 300 days following treatment with surgical amputation followed by standard chemotherapy. Immunohistochemistry was performed to confirm expression of HES1. Data from RT-qPCR and immunohistochemical (IHC) experiments were analyzed using REST2009 software and survival analysis based on IHC expression employed the Kaplan-Meier method and log rank analysis. Unbiased clustered images were generated from gene array analysis data for Notch/HES1 associated genes. Gene array analysis of Notch/HES1 associated genes suggested alterations in the Notch signaling pathway may contribute to the development of canine OSA. HES1 mRNA expression was elevated in tumor samples relative to normal bone, but decreased in tumor samples from dogs with a DFI < 100 days relative to those with a DFI > 300 days. NOTCH2 and HEY1 mRNA expression was also elevated in tumors relative to normal bone, but was not differentially expressed between the DFI tumor groups. Survival analysis confirmed an association between decreased HES1 immunosignal and shorter DFI. CONCLUSIONS: Our findings suggest that activation of Notch signaling occurs and may contribute to the development of canine OSA. However, association of low HES1 expression and shorter DFI suggests that mechanisms that do not alter HES1 expression may drive the most aggressive tumors.
format Online
Article
Text
id pubmed-3701487
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37014872013-07-05 HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors Dailey, Deanna D Anfinsen, Kristin P Pfaff, Liza E Ehrhart, EJ Charles, J Brad Bønsdorff, Tina B Thamm, Douglas H Powers, Barbara E Jonasdottir, Thora J Duval, Dawn L BMC Vet Res Research Article BACKGROUND: Hairy and enhancer of split 1 (HES1), a basic helix-loop-helix transcriptional repressor, is a downstream target of Notch signaling. Notch signaling and HES1 expression have been linked to growth and survival in a variety of human cancer types and have been associated with increased metastasis and invasiveness in human osteosarcoma cell lines. Osteosarcoma (OSA) is an aggressive cancer demonstrating both high metastatic rate and chemotherapeutic resistance. The current study examined expression of Notch signaling mediators in primary canine OSA tumors and canine and human osteosarcoma cell lines to assess their role in OSA development and progression. RESULTS: Reverse transcriptase - quantitative PCR (RT-qPCR) was utilized to quantify HES1, HEY1, NOTCH1 and NOTCH2 gene expression in matched tumor and normal metaphyseal bone samples taken from dogs treated for appendicular OSA at the Colorado State University Veterinary Teaching Hospital. Gene expression was also assessed in tumors from dogs with a disease free interval (DFI) of <100 days compared to those with a DFI > 300 days following treatment with surgical amputation followed by standard chemotherapy. Immunohistochemistry was performed to confirm expression of HES1. Data from RT-qPCR and immunohistochemical (IHC) experiments were analyzed using REST2009 software and survival analysis based on IHC expression employed the Kaplan-Meier method and log rank analysis. Unbiased clustered images were generated from gene array analysis data for Notch/HES1 associated genes. Gene array analysis of Notch/HES1 associated genes suggested alterations in the Notch signaling pathway may contribute to the development of canine OSA. HES1 mRNA expression was elevated in tumor samples relative to normal bone, but decreased in tumor samples from dogs with a DFI < 100 days relative to those with a DFI > 300 days. NOTCH2 and HEY1 mRNA expression was also elevated in tumors relative to normal bone, but was not differentially expressed between the DFI tumor groups. Survival analysis confirmed an association between decreased HES1 immunosignal and shorter DFI. CONCLUSIONS: Our findings suggest that activation of Notch signaling occurs and may contribute to the development of canine OSA. However, association of low HES1 expression and shorter DFI suggests that mechanisms that do not alter HES1 expression may drive the most aggressive tumors. BioMed Central 2013-07-01 /pmc/articles/PMC3701487/ /pubmed/23816051 http://dx.doi.org/10.1186/1746-6148-9-130 Text en Copyright © 2013 Dailey et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Dailey, Deanna D
Anfinsen, Kristin P
Pfaff, Liza E
Ehrhart, EJ
Charles, J Brad
Bønsdorff, Tina B
Thamm, Douglas H
Powers, Barbara E
Jonasdottir, Thora J
Duval, Dawn L
HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors
title HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors
title_full HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors
title_fullStr HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors
title_full_unstemmed HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors
title_short HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors
title_sort hes1, a target of notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701487/
https://www.ncbi.nlm.nih.gov/pubmed/23816051
http://dx.doi.org/10.1186/1746-6148-9-130
work_keys_str_mv AT daileydeannad hes1atargetofnotchsignalingiselevatedincanineosteosarcomabutreducedinthemostaggressivetumors
AT anfinsenkristinp hes1atargetofnotchsignalingiselevatedincanineosteosarcomabutreducedinthemostaggressivetumors
AT pfafflizae hes1atargetofnotchsignalingiselevatedincanineosteosarcomabutreducedinthemostaggressivetumors
AT ehrhartej hes1atargetofnotchsignalingiselevatedincanineosteosarcomabutreducedinthemostaggressivetumors
AT charlesjbrad hes1atargetofnotchsignalingiselevatedincanineosteosarcomabutreducedinthemostaggressivetumors
AT bønsdorfftinab hes1atargetofnotchsignalingiselevatedincanineosteosarcomabutreducedinthemostaggressivetumors
AT thammdouglash hes1atargetofnotchsignalingiselevatedincanineosteosarcomabutreducedinthemostaggressivetumors
AT powersbarbarae hes1atargetofnotchsignalingiselevatedincanineosteosarcomabutreducedinthemostaggressivetumors
AT jonasdottirthoraj hes1atargetofnotchsignalingiselevatedincanineosteosarcomabutreducedinthemostaggressivetumors
AT duvaldawnl hes1atargetofnotchsignalingiselevatedincanineosteosarcomabutreducedinthemostaggressivetumors